Stevanato Group S.p.A. (STVN) closed at $14.10 on Nov 3, 2026, down 28.6% on the day. The stock is down 29.7% over the past month, down 29.9% over three months, down 29.7% year to date and down 42.7% over the past year (since Nov 3, 2025). It trades 47.6% below its 52-week high of $26.90 and 9.8% above its 52-week low of $12.84. The close sits below its 50-day moving average ($20.36) and below its 200-day moving average ($18.04).
STVN is scheduled to report earnings on Nov 3, 2026, after market close.
Revenue up 8%, but stock price crashed 28%—what's going on with STVN?
The financial report is solid, but the crash is due to a single GLP-1 client cutting orders in 2027; The business is mature and valuations have shrunk significantly, but recovery will have to wait for orders to be fulfilled
Nov 4, 2026
Stevanato Group S.p.A. is scheduled to report on Nov 3, 2026, after market close.
No — the Nov 3, 2026 close of $14.10 is 21.8% below the 200-day average of $18.04.
STVN closed 47.6% below its 52-week high of $26.90.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
